Report copyright - Case Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic ... · Since 2011, eculizumab, a recombinant humanized anti-C5 monoclonal antibody, has been licensed
Please pass captcha verification before submit form